⌘K

Login Start Free

Home/Filings/4/0001562180-23-006130

4//SEC Filing

Meury William 4

Accession 0001562180-23-006130

CIK 0001395937other

View on SEC.gov Company Profile

Filed

Aug 2, 8:00 PM ET

Accepted

Aug 3, 9:12 AM ET

Size

19.0 KB

Accession

0001562180-23-006130

Insider Transaction Report

Form 4

Period: 2023-08-02

Syndax Pharmaceuticals IncSNDX

Director

Transactions

Exercise/Conversion
Common Stock
2023-08-02$7.11/sh+35,000$248,850→ 83,000 total
Exercise/Conversion
Common Stock
2023-08-02$9.47/sh+24,000$227,280→ 72,000 total
Sale
Common Stock
2023-08-02$20.45/sh−24,000$490,913→ 48,000 total
Exercise/Conversion
Stock Options (Right to buy)
2023-08-02−24,000→ 0 total
Exercise: $7.88Exp: 2029-06-10→ Common Stock (24,000 underlying)
Sale
Common Stock
2023-08-02$20.46/sh−35,000$715,946→ 48,000 total
Exercise/Conversion
Common Stock
2023-08-02$7.88/sh+24,000$189,120→ 72,000 total
Sale
Common Stock
2023-08-02$20.46/sh−24,000$490,951→ 48,000 total
Exercise/Conversion
Stock Options (Right to buy)
2023-08-02−24,000→ 0 total
Exercise: $9.47Exp: 2030-02-12→ Common Stock (24,000 underlying)
Exercise/Conversion
Stock Options (Right to buy)
2023-08-02−35,000→ 0 total
Exercise: $7.11Exp: 2028-09-25→ Common Stock (35,000 underlying)

Footnotes (4)

[F1]The sale prices ranged from $20.29 to $21.00.
[F2]The sale prices ranged from $20.30 to $20.97.
[F3]The sale prices ranged from $20.2950 to $20.89.
[F4]This option is fully vested.

Documents

1 file

4
primarydocument.xmlPrimary
PRIMARY DOCUMENT

Issuer

Syndax Pharmaceuticals Inc

CIK 0001395937

Entity typeother

Related Parties

1

filerCIK 0001536778

Filing Metadata

Form type: 4
Filed: Aug 2, 8:00 PM ET
Accepted: Aug 3, 9:12 AM ET
Size: 19.0 KB

View on SEC.gov